<a href="https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market">Complement 3 Glomerulopathy (C3G) Market</a>
Complement 3 Glomerulopathy (C3G) is a group of rare kidneys diseases that are driven by dysregulation of the complement cascade. It is a type of glomerular disease, which is characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a major amount of immunoglobulin and without deposition of C1q and C4.
The term C3G covers the dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) that are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when seen under a microscope. People with DDD generally present at a younger age (childhood or adolescence) as compared to people with C3GN (adulthood).
Complement 3 Glomerulopathy Epidemiological Segmentation
The Epidemiological Segmentation of Complement 3 Glomerulopathy in 7MM from 2020 to 2034 is segmented as:-
<ul>
<li>Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G)</li>
<li>Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G)</li>
<li>Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G)</li>
</ul>
<a href="https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-epidemiology-forecast">Complement 3 Glomerulopathy Epidemiology</a>
<ul>
<li>The total diagnosed prevalent population of C3G in the 7MM was found to be ~5,760 in 2023.</li>
<li>The diagnosed prevalent population of C3G, in the United States, was found to be 3,372 in 2023.</li>
</ul>
Complement 3 Glomerulopathy Market
The market size of Complement 3 Glomerulopathy in the 7MM was ~USD 35 million in 2023.
Complement 3 Glomerulopathy Market Drivers
<ul>
<li>Intermediate Pipeline Activity</li>
<li>Increase in Awareness</li>
<li>The advent of Biomarkers in Near Future</li>
</ul>
Complement 3 Glomerulopathy Market Barriers
<ul>
<li>Hurdles in Clinical Trial Settings</li>
<li>Drawbacks of Renal Replacement Therapy</li>
<li>Prone to Recurrence</li>
<li>The Dominance of off-label Therapies</li>
</ul>
Complement 3 Glomerulopathy Emerging Drugs
The emerging drugs of the Complement 3 Glomerulopathy market are
<ul>
<li>ADX-097 (Q32 Bio Inc.)</li>
<li>Pegcetacoplan (Apellis Pharmaceuticals, Inc.)</li>
<li>Iptacopan (Novartis Pharmaceuticals)</li>
<li>And many others.</li>
<li>Complement 3 Glomerulopathy Key Players</li>
<li>The key players in the Complement 3 Glomerulopathy market are</li>
<li>Q32 Bio Inc.</li>
<li>Apellis Pharmaceuticals</li>
<li>Novartis Pharmaceuticals, and many others.</li>
</ul>

Complement 3 Glomerulopathy (C3G) Market

Complement 3 Glomerulopathy (C3G) Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.